Dual carbapenem-fluoroquinolone resistance in community-onset pediatric urinary tract infections: Phenotypic-genotypic integration in three cases

Conflict of interest statement

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

Written informed consents were obtained from the patients' families for the publication of these case reports. Institutional approval for case publication was granted by the Department of Pediatric Cardiology and Nephrology, Can Tho Children's Hospital (Approval No. CV-BN03/TM/BVN CT/2025).

Funding

The authors received no extramural funding for the study.

Authors’ contributions

QNC: Conceived and designed the study, curated and collected data, drafted the manuscript. HTD: Supervised the project, critically reviewed and revised the manuscript for important intellectual content. THT: Performed laboratory analyses, prepared the illustrative figure, reviewed and revised the manuscript. NNQ: Verified data accuracy, reviewed and revised the manuscript. MLH: Verified data accuracy, reviewed and revised the manuscript.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by Pan Y, Lei Y, Zhang Q

Acknowledgements

We sincerely thank Can Tho University of Medicine and Pharmacy for their professional support and valuable feedback during the preparation of this report. We also express our gratitude to the pediatric patients and their families for their cooperation. During manuscript preparation, we used ChatGPT (OpenAI) to improve clarity and language; all authors reviewed and take full responsibility for the final content.

References

[1] Esposito S, Biasucci G, Pasini A, Predieri B, Vergine G, Crisafi A, et al. Antibiotic resistance in paediatric febrile urinary tract infections. J Glob Antimicrob Resist 2022; 29: 499-506. doi: 10.1016/j.jgar.2021.11.003

[2] Do Tran H, Trnng Nguyen B, Quang Tran H, Gia Tran H. A crosssectional study of the antibiotic resistant prevalence of ESBL-producing Enterobacteriaceae in Vietnam. J Health Sci 2022; 12(3): 1884-1888 doi: 10.17532/jhsci.2022.1689.

[3] El Zein Z, Boutros CF, El Masri M, Tawil EE, Sraj M, Salameh Y, et al. The challenge of multidrug resistance in hospitalized pediatric patients with urinary tract infections. Front Cell Infect Microbiol 2025; 15: 1570405. doi: 10.3389/fcimb.2025.1570405.

[4] Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis 2024. doi:10.1093/cid/ciae403.

[5] Fisher M, Komarow L, Kahn J, Patel G, Revolinski S, Huskins WC, et al. Carbapenem-resistant Enterobacterales in children at 18 US health care system study sites: Clinical and molecular epidemiology from a prospective multicenter cohort study. Open Forum Infect Dis 2024; 11(2): ofad688. doi: 10.1093/ofid/ofad688.

[6] Yee R, Bard JD, Simner PJ. The genotype-to-phenotype dilemma: How should laboratories approach discordant susceptibility results? J Clin Microbiol 2021; 59(6): e00138-20. doi: 10.1128/jcm.00138-20.

[7] Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22(1): 161-182. doi: 10.1128/cmr.00036-08.

[8] Hooper DC, Jacoby GA. Mechanisms of drug resistance: Quinolone resistance. Ann N Y Acad Sci 2015; 1354(1): 12-31. doi: 10.1111/nyas.12830.

[9] Zohar I, Maor Y, Shirin N, Yahav D. Current management strategies for multidrug-resistant Gram-negative urinary tract infections, a focus on aminoglycosides monotherapy. CMI Commun 2024; 1(2): 105039. doi: 10.1016/j.cmicom.2024.105039.

[10] Kılıç FE, Küçükkelepçe O. Evaluating antibiotic resistance in pediatric UTIs: Five-year data from a tertiary hospital in Turkey. Turk J Pediatr 2025; 61(3): 402.doi.org/10.3390/medicina61030402.